Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

Article  PubMed  CAS  Google Scholar 

Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70:299–312.

Article  PubMed  Google Scholar 

Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2016;15:660.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ghajar-Rahimi G, Kang K-D, Totsch SK, Gary S, Rocco A, Blitz S, et al. Clinical advances in oncolytic virotherapy for pediatric brain tumors. Pharmacol Ther. 2022;239:108193.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yuan B, Wang G, Tang X, Tong A, Zhou L. Immunotherapy of glioblastoma: recent advances and future prospects. Hum Vaccin Immunother. 2022;18:2055417.

Article  PubMed  PubMed Central  Google Scholar 

Harrington K, Freeman DJ, Kelly B, Harper J, Soria J-C. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18:689–706.

Article  PubMed  CAS  Google Scholar 

Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329–36.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023;31:134–53.

Article  PubMed  CAS  Google Scholar 

Thambi T, Hong J, Yoon A-R, Yun C-O. Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses. Cancer Gene Ther. 2022;29:1321–31.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879–85.

Article  PubMed  CAS  Google Scholar 

Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003;9:555–61.

PubMed  CAS  Google Scholar 

Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012;2012:805629.

Article  PubMed  PubMed Central  Google Scholar 

Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 2001;8:746–59.

Article  PubMed  CAS  Google Scholar 

Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 2001;8:1618–26.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006;14:107–17.

Article  PubMed  CAS  Google Scholar 

Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 2005;12:673–81.

Article  PubMed  CAS  Google Scholar 

Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62:6070–9.

PubMed  CAS  Google Scholar 

Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. J Clin Invest. 2019;129:1407–18.

Article  PubMed  PubMed Central  Google Scholar 

Wong HH, Lemoine NR, Wang Y. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses. 2010;2:78–106.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vassilaki N, Frakolaki E. Virus-host interactions under hypoxia. Microbes Infect. 2017;19:193–203.

Article  PubMed  CAS  Google Scholar 

Shen BH, Hermiston TW. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther. 2005;12:902–10.

Article  PubMed  CAS  Google Scholar 

Schmid M, Ernst P, Honegger A, Suomalainen M, Zimmermann M, Braun L, et al. Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Commun. 2018;9:450.

Article  PubMed  PubMed Central  Google Scholar 

Mu M, Chen H, Fan R, Wang Y, Tang X, Mei L, et al. A tumor-specific ferric-coordinated epigallocatechin-3-gallate cascade nanoreactor for glioblastoma therapy. J Adv Res. 2021;34:29–41.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang X, Sun C, Li P, Wu T, Zhou H, Yang D, et al. Vaccine engineering with dual-functional mineral shell: a promising strategy to overcome preexisting immunity. Adv Mater. 2016;28:694–700.

Article  PubMed  CAS  Google Scholar 

Chen J, Gao P, Yuan S, Li R, Ni A, Chu L, et al. Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy. ACS Nano. 2016;10:11548–60.

Article  PubMed  CAS  Google Scholar 

Mu M, Liang X, Zhao N, Chuan D, Chen B, Zhao S, et al. Boosting ferroptosis and microtubule inhibition for antitumor therapy via a carrier-free supermolecule nanoreactor. J Pharm Anal. 2023;13:99–109.

Article  PubMed  Google Scholar 

Xue C-C, Li M-H, Zhao Y, Zhou J, Hu Y, Cai K-Y, et al. Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO(3) nanoformulation triggers ferroptosis in target tumor cells. Sci Adv. 2020;6:eaax1346.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang L, Wan S-S, Li C-X, Xu L, Cheng H, Zhang X-Z. An adenosine triphosphate-responsive autocatalytic fenton nanoparticle for tumor ablation with self-supplied H(2)O(2) and acceleration of Fe(III)/Fe(II) conversion. Nano Lett. 2018;18:7609–18.

Article  PubMed  CAS  Google Scholar 

Chen J, Chen F, Zhang L, Yang Z, Deng T, Zhao Y, et al. Self-assembling porphyrins as a single therapeutic agent for synergistic cancer therapy: a one stone three birds strategy. ACS Appl Mater Interfaces. 2021;13:27856–67.

Article  PubMed  CAS  Google Scholar 

Pan C, Ou M, Cheng Q, Zhou Y, Yu Y, Li Z, et al. Z-scheme heterojunction functionalized pyrite nanosheets for modulating tumor microenvironment and strengthening photo/chemodynamic therapeutic effects. Adv Funct Mater. 2020;30:1906466.

Article  CAS  Google Scholar